A systematic meta-analysis has corroborated these findings, confirming a significant association between GLP-1RA utilization and reduced glaucoma incidence in retrospective studies [108]
Concurrent conditions such as anaemia, thyroid dysfunction, depression, sleep disorders, or inadequate nutritional intake should be investigated, particularly if fatigue is severe or worsening
For most patients, a BMI of 30 or greater represents the primary qualification threshold for GLP-1 weight loss treatment
The medication became available by prescription in early January 2026, offering a non-injectable alternative to the weekly Wegovy injection
By combining three receptor targets into a single molecule, researchers aim to achieve enhanced reduction of weight, improved blood glucose control, and potentially greater metabolic flexibility compared to earlier therapies